Frontier Medicines unveiled promising preclinical data for FMC-220, a novel covalent activator of mutant p53 Y220C, demonstrating durable anti-tumor activity across multiple cancer models including those with KRAS co-mutations.
Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.